ClinConnect ClinConnect Logo
Search / Trial NCT04605081

Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a)

Launched by YALE UNIVERSITY · Oct 21, 2020

Trial Information

Current as of July 01, 2025

Enrolling by invitation

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Be in the age range ≥18 years of age and ≤70 years of age.
  • Have had laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy
  • Approximately ten months post-surgery
  • Experienced regular loss of control eating about six months after bariatric surgery, and were considered treatment responders to a four-month treatment trial of medication and/or BWL
  • Be an otherwise healthy subject without uncontrolled medical problems, as determined by the study physician and medical co-investigators (physical examination, laboratory studies).
  • Read, comprehend, and write English at a sufficient level to complete study-related materials.
  • Provide a signed and dated written informed consent prior to study participation.
  • Be available for participation in the study for up to 15 months (3-month treatment plus 12-month follow up).
  • Exclusion Criteria:
  • Has a predisposition to seizures (e.g., subject with a history or evidence of seizure disorder, febrile seizures during childhood, brain tumor, cerebrovascular disease, or significant head trauma; has a family history of idiopathic seizure disorder or is currently being treated with medications or treatment regimens that lower seizure threshold).
  • Has a history of anorexia nervosa or history of bulimia nervosa.
  • Is currently taking a medication that is a contraindication to NB medication (e.g., MAOI, opiates).
  • Is currently using other medications for weight loss.
  • Has a history of allergy or sensitivity to bupropion or naltrexone.
  • Has a co-existing psychiatric condition that requires hospitalization or more intensive treatment (such as bipolar mood disorders, psychotic illnesses, or severe depression)
  • Has untreated hypertension with a seated systolic blood pressure \> 160 mmHg, diastolic blood pressure \> 100 mmHg, or heart rate \> 100 beats/minute.
  • Has a history of congenital heart disease, cardiovascular disease, cardiac arrhythmias requiring medication, or a history of cerebrovascular pathology including stroke.
  • Has current uncontrolled hypertension.
  • Has current uncontrolled Type I or Type II diabetes mellitus.
  • Has untreated hypothyroidism with a TSH \> 1.5 times the upper limit of normal for the - test laboratory with repeat value that also exceeds this limit.
  • Has gallbladder disease.
  • Has a history of severe renal, hepatic, neurological, chronic pulmonary disease, or any other unstable medical disorder.
  • Has a recent history of drug or alcohol dependence (since having bariatric surgery).
  • Is currently in active treatment for eating or weight loss.
  • Is currently participating in another clinical study in which the subject is or will be exposed to an investigational or a non-investigational drug or device.
  • Is breast-feeding or is pregnant or is not using a reliable form of birth control.
  • Reports active suicidal or homicidal ideation.

About Yale University

Yale University, a prestigious Ivy League institution located in New Haven, Connecticut, is renowned for its commitment to advancing medical research and clinical innovation. With a rich history of academic excellence and a robust infrastructure for scientific inquiry, Yale serves as a leading sponsor for clinical trials aimed at improving patient care and developing new therapeutic approaches. The university's multidisciplinary teams of researchers and clinicians collaborate to conduct rigorous and ethical studies, leveraging cutting-edge technologies and methodologies to address critical health challenges. Through its dedication to fostering an environment of inquiry and discovery, Yale University plays a pivotal role in translating research findings into clinical practice, ultimately enhancing health outcomes for diverse populations.

Locations

New Haven, Connecticut, United States

Patients applied

0 patients applied

Trial Officials

Valentina Ivezaj, Ph.D.

Principal Investigator

Yale University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials